JNJ/PTGX: JNJ2113: Concerns over upcoming (Q1) oral IL23 ANTHEM trial in Ulcerative Colitis

With JNJ2113's (icotrokinra) upcoming ulcerative colitis ANTHEM-UC trial reading out this first quarter, our unique UC specific analysis highlights clinical concerns that may limit JNJ/PTGX's oral JNJ2113's utility in UC, regardless of emerging oral competitors and high efficacy next-gen injectable IL23s.